Astrazeneca PLC’s (AZN) Sell Rating Reiterated at Goldman Sachs Group Inc.
Astrazeneca PLC (NYSE:AZN)‘s stock had its “sell” rating reissued by equities research analysts at Goldman Sachs Group Inc. in a research report issued on Wednesday.
A number of other research firms have also recently commented on AZN. Beaufort Securities reissued a “hold” rating on shares of Astrazeneca PLC in a report on Thursday, August 11th. Citigroup Inc. reissued a “buy” rating on shares of Astrazeneca PLC in a report on Saturday, June 25th. Jefferies Group raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Monday, September 12th. Shore Capital reissued a “hold” rating on shares of Astrazeneca PLC in a report on Wednesday, July 20th. Finally, Argus initiated coverage on shares of Astrazeneca PLC in a report on Tuesday, July 12th. They issued a “hold” rating for the company. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $37.44.
Shares of Astrazeneca PLC (NYSE:AZN) traded up 0.09% on Wednesday, reaching $32.29. 4,009,040 shares of the company were exchanged. Astrazeneca PLC has a 12 month low of $26.97 and a 12 month high of $35.04. The company has a market cap of $81.69 billion, a price-to-earnings ratio of 36.90 and a beta of 0.75. The company’s 50-day moving average price is $33.23 and its 200 day moving average price is $30.79.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/08/astrazeneca-plcs-azn-sell-rating-reiterated-at-goldman-sachs-group-inc.html
Astrazeneca PLC (NYSE:AZN) last posted its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping analysts’ consensus estimates of $0.76 by $0.07. The firm earned $5.60 billion during the quarter, compared to analysts’ expectations of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The business’s revenue for the quarter was down 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.21 earnings per share. On average, equities research analysts expect that Astrazeneca PLC will post $2.97 EPS for the current year.
The business also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were paid a dividend of $0.44 per share. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is presently 78.29%.
A number of institutional investors have recently modified their holdings of AZN. Dodge & Cox boosted its stake in Astrazeneca PLC by 121.2% in the first quarter. Dodge & Cox now owns 26,049,650 shares of the company’s stock worth $733,558,000 after buying an additional 14,272,518 shares during the last quarter. Primecap Management Co. CA boosted its stake in Astrazeneca PLC by 1,223.1% in the first quarter. Primecap Management Co. CA now owns 13,084,275 shares of the company’s stock worth $368,453,000 after buying an additional 12,095,375 shares during the last quarter. Capital International Investors boosted its stake in Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock worth $618,094,000 after buying an additional 3,705,199 shares during the last quarter. BlackRock Investment Management LLC boosted its stake in Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock worth $217,580,000 after buying an additional 3,046,268 shares during the last quarter. Finally, Becker Capital Management Inc. acquired a new stake in Astrazeneca PLC during the second quarter worth approximately $35,701,000. Institutional investors and hedge funds own 11.39% of the company’s stock.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.